Developing new, accurate, less intrusive, early stage and cost-efficient diagnostic methods is one of the major objectives in the pharma industry.
Finding signatures that could predict or detect a disease in the early stages is an intrinsic multidisciplinary process.
Eremid™’s “multi-omics” capacity and experience make us the perfect partner during the pre-clinal research and development stages of the diagnostic method development. Whether the goal is a specific molecule (metabolite or nucleic acid) or a signature associated with specific disease, our team can design and execute the right assay not only from a biological perspective, but also finding the most time-effective, cost-effective and easy to translate in a regulatory environment, method.
